DISCUSSION
Hemospray is a proprietary hemostatic powder, which is licensed in Europe and Canada for the management of nonvariceal upper GI hemorrhage. It achieves hemostasis by absorbing moisture to form a mechanical barrier, and it has the ability to cover large areas with multiple bleeding points without the need for precise targeting of lesions. Before application, the carbon dioxide canister is activated and the endoscope working channel is flushed with air to remove moisture. The supplied 10F catheter is passed down the working channel until approximately 1 cm of the tip is visualized and positioned 1 to 2 cm away from the bleeding site. Contact with blood should be avoided because this may result in clotting of Hemospray within the catheter. Once positioned, Hemospray is applied in multiple bursts of 1 to 2 seconds until hemostasis is achieved.
PHG is a common and potentially fatal adverse event of cirrhosis, with severity correlating with the degree of portal hypertension 1 ; it is characterized endoscopically by mucosal erythema with a mosaic, snakeskin pattern. 2 One series reported a prevalence of 80% in individuals with cirrhosis, with an 18-month acute bleeding risk of 2.5% and bleeding-related mortality of 12.5%. 1 There is limited evidence supporting the role of nonselective b-blockers (NSBB) and terlipressin for bleeding PHG. 2 The Baveno VI portal hypertension guidelines recommend that NSBB be used in the secondary prevention of bleeding PHG and that transjugular intrahepatic portosystemic stent shunt (TIPSS) be considered for transfusion-dependent patients in whom NSBB has failed. 3 Because alcohol cessation per se may reduce portal pressures, an effective endoscopic option is required in addition to medical adjuncts to rapidly achieve hemostasis and avoid unnecessary transfusion or TIPSS.
It is arguable that the endoscopic appearances included in this report may be consistent with gastric antral vascular ectasia (GAVE). Indeed, GAVE is often antral predominant, may complicate cirrhosis in up to 30% of cases, 2 and differs from PHG (Table 1) . However, the snakeskin appearance of Figure 1 . Diffuse bleeding at the gastric antrum.
Written transcript of the video audio is available online at www.VideoGIE.org. the underlying mucosa and the presence of cirrhosis led us to favor PHG over GAVE. Before Hemospray, argon plasma coagulation, band ligation, and cryotherapy had been used for bleeding PHG with limited success. 2 However, the efficacy and safety of Hemospray have now been demonstrated in case series for both PHG and GAVE. 4, 5 Our video case report demonstrates the ease of application and effectiveness of Hemospray in this situation, potentially revolutionizing the endoscopic management of bleeding PHG.
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